Biohaven (BHVN) Non Operating Income (2021 - 2026)
Biohaven (BHVN) posted Non Operating Income of $168000.0 for Q1 2026, up 106.8% sequentially from -$2.5 million in Q4 2025, and down 65.92% YoY from $493000.0 in Q1 2025.
Analysis
Biohaven (BHVN) Non Operating Income (2021 - 2026) Analysis & Trends
Biohaven has reported Non Operating Income for 6 years, with the latest figure at $168000.0 in Q1 2026.
- Quarterly Non Operating Income fell 65.92% year-over-year to $168000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 million (down 78.45% YoY) and the FY2025 annual result came in at $8.0 million, down 79.71% from the prior year.
- Non Operating Income rose to $168000.0 in Q1 2026 per BHVN's latest filing, from -$2.5 million in the prior quarter.
- Over five years, Non Operating Income peaked at $17.8 million in Q3 2024 and troughed at -$3.8 million in Q3 2025.
- A 5-year average of $4.5 million and a median of $3.7 million in 2024 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income sank 226.41% in 2022, then surged 205825.0% in 2023.
- Over 5 years, Non Operating Income stood at -$1.8 million in 2022, then surged by 521.27% to $7.7 million in 2023, then sank by 59.5% to $3.1 million in 2024, then sank by 178.76% to -$2.5 million in 2025, then surged by 106.8% to $168000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $168000.0, -$2.5 million, and -$3.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Biohaven | 2.35 Bn | 2.09 Bn | - | -12.02 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -12.02 Mn |
| Mar 31, 2026 | 168,000.00 |
| Dec 31, 2025 | -2.47 Mn |
| Sep 30, 2025 | -3.84 Mn |
| Jun 30, 2025 | 13.82 Mn |
| Mar 31, 2025 | 493,000.00 |
| Dec 31, 2024 | 3.14 Mn |
| Sep 30, 2024 | 17.81 Mn |
| Jun 30, 2024 | 14.18 Mn |
| Mar 31, 2024 | 4.31 Mn |
| Dec 31, 2023 | 7.74 Mn |
| Sep 30, 2023 | 4.69 Mn |
| Jun 30, 2023 | 5.84 Mn |
| Mar 31, 2023 | 8.23 Mn |
| Dec 31, 2022 | -1.84 Mn |
| Jun 30, 2022 | -67,000.00 |
| Mar 31, 2022 | -4,000.00 |
| Dec 31, 2021 | 1.45 Mn |
| Sep 30, 2021 | -5,000.00 |